TY - JOUR T1 - Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic AU - Skolariki, Aglaia AU - D'Costa, Jamie AU - Little, Martin AU - Lord, Simon Y1 - 2022/// JO - Exploration of Targeted Anti-tumor Therapy VL - 3 IS - 2 SP - 172 EP - 199 DO - 10.37349/etat.2022.00078 UR - https://www.explorationpub.com/Journals/etat/Article/100278 AB - The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions. ER -